Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study

BACKGROUND: High-grade serous ovarian carcinoma (HGSOC) is characterized by TP53 mutations, DNA repair defects, and genomic instability. We hypothesized that prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type HGSOC. METHODS: In this open label, single ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Min, Nair, Jayakumar, Zimmer, Alexandra, Lipkowitz, Stanley, Annunziata, Christina M., Merino, Maria J., Swisher, Elizabeth M., Harrell, Maria I., Trepel, Jane B., Lee, Min-Jung, Bagheri, Mohammad H., Botesteanu, Dana-Adriana, Steinberg, Seth M., Minasian, Lori, Ekwede, Irene, Kohn, Elise C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366122/
https://www.ncbi.nlm.nih.gov/pubmed/29361470
http://dx.doi.org/10.1016/S1470-2045(18)30009-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366122/
https://www.ncbi.nlm.nih.gov/pubmed/29361470
http://dx.doi.org/10.1016/S1470-2045(18)30009-3

Ejemplares similares